CRI Funded Scientists

Jedd D. Wolchok, MD, PhD, Clinical Accelerator Investigator

Weill Cornell Medicine

Area of Research: Cáncer de mama, Cervical Cancer, Colorectal Cancer, Kidney Cancer, Melanoma, Ovarian Cancer

Dr. Jedd D. Wolchok is the Meyer Director of the Sandra and Edward Meyer Cancer Center and a professor of medicine at Weill Cornell Medicine.

Prior to joining Weill Cornell Medicine in 2022, he was the Lloyd J. Old/Virginia and Daniel K. Ludwig Chair in Clinical Investigation; Chief, Immuno-Oncology Service, Human Oncology and Pathogenesis Program; director, Parker Institute for Cancer Immunotherapy; and associate director, the Ludwig Center for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center.

Dr. Wolchok has been at the forefront of cancer immunotherapy and is renowned for leading the clinical trials that led to the first FDA-approved checkpoint inhibitor immunotherapy, the anti-CTLA-4 antibody ipilimumab. He continues to lead clinical trials aimed at expanding immunotherapy’s benefits to more patients. He also conducts research that focuses on the GITR and OX40 pathways, as well as how some immune cells, known as myeloid-derived suppressor cells, influence anti-tumor immune responses.

In addition to his role as an associate director of CRI’s Scientific Advisory Council, Dr. Wolchok serves on the CLIP Grant Review Committee and is also a member of CRI’s Clinical Leadership Committee.

Projects and Grants

A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab (NCT01975831)

Memorial Sloan Kettering Cancer Center | Breast Cancer, Cervical Cancer, Colorectal Cancer, Kidney Cancer, Ovarian Cancer | 2013

Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors (TRX518-001) (NCT01239134)

Memorial Sloan Kettering Cancer Center | Melanoma | 2010

This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.